15 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Recent advances in nuclear receptor-binding SET domain 2 (NSD2) inhibitors: An update and perspectives.
China Pharmaceutical University
NSD3: Advances in cancer therapeutic potential and inhibitors research.
Peking University
Drug Discovery Targeting Nuclear Receptor Binding SET Domain Protein 2 (NSD2).
University of Texas Medical Branch (UTMB)
Discovery of a New-Generation S-Adenosylmethionine-Noncompetitive Covalent Inhibitor Targeting the Lysine Methyltransferase Enhancer of Zeste Homologue 2.
Sun Yat-Sen University
Structural Modification and Pharmacological Evaluation of Substituted Quinoline-5,8-diones as Potent NSD2 Inhibitors.
Shanghai Jiao Tong University
Structure-Aided Design, Synthesis, and Biological Evaluation of Potent and Selective Non-Nucleoside Inhibitors Targeting Protein Arginine Methyltransferase 5.
Sun Yat-Sen University
Discovery of a First-in-Class Degrader for Nuclear Receptor Binding SET Domain Protein 2 (NSD2) and Ikaros/Aiolos.
Icahn School of Medicine At Mount Sinai
Structure-Based Discovery of a Series of NSD2-PWWP1 Inhibitors.
Chinese Academy of Sciences
5-Aminonaphthalene derivatives as selective nonnucleoside nuclear receptor binding SET domain-protein 2 (NSD2) inhibitors for the treatment of multiple myeloma.
Chinese Academy of Sciences
Discovery of Small-Molecule Antagonists of the PWWP Domain of NSD2.
University of Toronto
Computational discovery and biological evaluation of novel inhibitors targeting histone-lysine N-methyltransferase SET7.
China Pharmaceutical University
Novel inhibitors of As(III) S-adenosylmethionine methyltransferase (AS3MT) identified by virtual screening.
Astrazeneca
Sulfonamide-substituted cyanopyrrolidines with activity as DUB inhibitors
Mission Therapeutics